ACADIA Pharmaceuticals, Inc. (NASDAQ:ACAD) Q3 2022 Earnings Conference Call November 2, 2022 4:30 PM ET
Company Participants
Mark Johnson - VP, IR
Stephen Davis - CEO & Director
Brendan Teehan - EVP, COO & Head, Commercial
Kathie Bishop - SVP and Head, Rare Disease & External Innovation
Srdjan Stankovic - President
Mark Schneyer - EVP & CFO
Conference Call Participants
Jeff Hung - Morgan Stanley
Neena Bitritto-Garg - Citi
Ritu Baral - Cowen and Company
Salveen Richter - Goldman Sachs
Jay Olson - Oppenheimer
Alex Nackenoff - Raymond James & Associates
Marc Goodman - SVB Securities
Gregory Renza - RBC Capital Markets
Yatin Suneja - Guggenheim Securities
Charles Duncan - Cantor Fitzgerald
Sumant Kulkarni - Canaccord Genuity
Operator
Good day, ladies and gentlemen, and welcome to ACADIA Pharmaceuticals Third Quarter 2022 Financial Results Conference Call. My name is Gigi, and I will be your coordinator for today. [Operator Instructions].
I would now like to turn the presentation over to Mark Johnson, Vice President of Investor Relations at ACADIA. Please proceed.
Mark Johnson
Thank you, Gigi. Good afternoon, and thank you for joining us on today's call to discuss ACADIA's third quarter 2022 financial results. Joining me on the call today from ACADIA are Stephen Davis, our Chief Executive Officer, who will provide an overview of our third quarter performance and a review of our business; Brendan Teehan, our Chief Operating Officer, Head of Commercial, will provide updates on our commercial performance; and Kathy Bishop, our Chief Scientific Officer and Head of will provide an overview of tripinetide; Dr. Srdjan Stankovic, our President, will then discuss our pipeline progress, Mark Schneider, our Chief Financial Officer, will discuss our financial results and guidance before turning it back to Steve for final remarks and opening the call up for your questions.
I would also like to point out that we're using supplement slides, which are available on the Events and Presentations section of our website.
Before we proceed, I would just like to remind you that during our call today, we will be making a number of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements, including goals, expectations, plans, prospects, growth potential, timing of events or future results are based on current information, assumptions and expectations that are inherently subject to change and involve a number of risks and uncertainties that may cause actual results to differ materially. These factors and other risks associated with our business can be found in our filings made with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of today's date.